Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Vitamin D deficiency common in patients with IBD, chronic liver disease

Vitamin D deficiency common in patients with IBD, chronic liver disease

October 06, 2008

New research presented at the 73rd Annual Scientific Meeting of the American College of Gastroenterology in Orlando found patients with inflammatory bowel disease or chronic liver disease were at increased risk of developing Vitamin D deficiencies. Two separate studies highlight the importance of regular Vitamin D checkups in the evaluation of patients with certain digestive diseases.

For IBD Patients, Vitamin D Deficiency Associated with Lower Quality of Life and Higher Disease Activity




Researchers at the Medical College of Wisconsin investigated whether Vitamin D deficiency in patients with IBD is associated with a lower quality of life or higher disease activity independent of other known risk factors and medication use.

Disease activity and quality of life were assessed using validated questionnaires, which were administered at every clinic visit. The researchers also looked at the prevalence and seasonality of Vitamin D deficiency in this inflammatory bowel disease population, as well as its association with IBD-related hospitalizations, surgeries and medication use.

This retrospective cohort study conducted by Dr. Alex Ulitsky and his colleagues analyzed vitamin D levels of 504 inflammatory bowel disease patients. They recorded the patients' lowest Vitamin D measurements and date when each low measurement was taken.

Dr. Ulitsky and his team found almost 50 percent of the patients were Vitamin D deficient at some point, with 11 percent being severely deficient. Vitamin D deficiency was not significantly associated with being hospitalized for IBD or having IBD-related surgeries. However, in both Crohn's disease (CD) and ulcerative colitis (UC) patients, vitamin D deficiency was independently associated with having increased disease activity scores compared to those with normal levels of Vitamin D. Vitamin D deficient CD patients, but not UC patients, had worse quality of life when compared to patients who were not Vitamin D deficient.

According to Dr. Ulitsky, "All IBD patients, irrespective of their disease, disease location or nature should have their Vitamin D levels checked regularly and corrected aggressively when insufficiency is found."

Vitamin D Deficiency Prevalent in Patients with Chronic Liver Disease

Researchers from the University of Tennessee in Memphis measured the vitamin D levels of 118 chronic liver disease patients. Researchers found 92.4 percent of chronic liver patients had some degree of vitamin D deficiency and at least one third were severely deficient. Severe vitamin D deficiency was more common among cirrhotics.

"Since deficiency is common among these patients, Vitamin D replacement may hopefully prevent osteoporosis and other bone complications related to end stage liver disease," said lead researcher Dr. Satheesh P. Nair.

The study included 43 hepatitis C patients with cirrhosis; 57 hepatitis C patients without cirrhosis; 18 cirrhosis patients without hepatitis C. The severity of vitamin D deficiency was divided into three groups: mild (between 20-32 ng/ml), moderate (between 7-20 ng/ml), and severe (less than 7 ng/ml).

Importance of Vitamin D and Bone Health

Vitamin D, a fat-soluble vitamin, helps the body absorb calcium and plays a crucial role in the growth and maintenance of strong, healthy bones. A lack of vitamin D causes calcium-depleted bone, which can weaken the bones and increase the risk of fractures resulting from osteoporosis.

A diet rich in vitamin D, such as fish, eggs, fortified milk, and cod liver oil, is essential to maintaining good bone health.

American College of Gastroenterology



Related Chronic Liver Disease Current Events and Chronic Liver Disease News Articles Chronic Liver Disease Current Events and Chronic Liver Disease News RSS Chronic Liver Disease Current Events and Chronic Liver Disease News RSS
UCSD researchers pave the way for effective liver treatments
A combination of bioengineering and medical research at the University of California, San Diego has led to a new discovery that could pave the way for more effective treatments for liver disease.

Probe position may change results in liver stiffness measurements in transient elastography
A major clinical challenge is to find the best method to evaluate and to manage the increasing numbers of patients with chronic liver disease. Liver biopsy, due to its risks and limitations, is no longer considered mandatory as the first-line indicator of liver injury, and several markers have been developed as non-invasive alternatives.

NEJM Study Points to New Era in Hepatitis C Treatment
For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

Liver disease 'shrunk' by blood-pressure drug
A blood-pressure medicine has been shown to reverse the effects of early-stage liver failure in some patients.

Hyperferritinemia is another surrogate marker of advanced liver disease
High serum ferritin, being a hallmark of hereditary hemochromatosis , is frequently found in chronic hepatitis C, alcoholic or non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients.

Diabetes, obesity and hypertension increase mortality in hepatitis C patients
The specific impact of metabolic syndrome on mortality in hepatitis C patients has been revealed by new research to be presented on Sunday April 26 at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.

A rigorous method for liver biopsy
Liver biopsy is still considered the gold standard for grading, staging and "stad-ging" the chronic liver disease. In addition, it remains a primary source for acquiring new knowledge on the liver pathology.

Hepatitis C Treatment Reduces the Virus but Liver Damage Continues
Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.

Mayo Clinic's new imaging technology accurately identifies a broad spectrum of liver disease
A new study shows that an imaging technology developed by Mayo Clinic researchers can identify liver fibrosis with high accuracy and help eliminate the need for liver biopsies. Liver fibrosis is a common condition that can lead to incurable cirrhosis if not treated in time.

If the diabetes has a direct carcinogenetic effect?
The association of DM2 with solid tumors, and particularly with HCC, has been long suspected and several studies have reported increased mortality rates for neoplastic diseases in patients with DM2.
More Chronic Liver Disease Current Events and Chronic Liver Disease News Articles
The Comfort of Home for Chronic Liver Disease: A Guide for Caregivers

The Comfort of Home for Chronic Liver Disease: A Guide for Caregivers
by Lucy Mathew NP (Author), Jill Chang (Author), Maria M. Meyer (Author), RN Paula Derr (Author)

Despite the growing number of hepatitis B and C and liver cancer patients in the United States, knowledge of liver disease is limited even among health care professionals. A caregiver that knows more about this complex affliction can greatly increase a patient's ability to cope. This disease-specific guide aims to educate and instruct both professional home-health aides and family caregivers, in order to ensure the patient's quality of life and comfort and help caregivers through challenging courses of treatment.

The Future of Hepatitis C

The Future of Hepatitis C
Directed By: ITV
Also With: ITV (Producer)



Parsley Root - For chronic liver and gallbladder diseases, water retention, kidney congestion, 2 oz., (Health Herb)

Parsley Root - For chronic liver and gallbladder diseases, water retention, kidney congestion, 2 oz., (Health Herb)
by HerbalLoveShop

Parsley is a diuretic, blood purifier, carminative, and hepatic. PARSLEY ROOT (Petroselinum sativum) Useful for chronic liver and gallbladder diseases. The roots act most readily on the kidneys in comparison to other parts of the plant. Combine Parsley Root with Plantain and Marshmallow Root for kidney and bladder infections. It is strengthening for weak and sensitive people simply by adding a couple slices fo the root to a soup. Other indications: difficult urination, dropsy, jaundice, all stones, liver and spleen obstructions, asthma, water retention, coughs, kidney congestion, tumors, female problems, and after-pains of birth. CAUTION: Do not use if inflammation of the kidneys is present. For chronic liver and gallbladder diseases, water retention, kidney congestion.

Balanceuticals Stomach Fortifier Dietary Supplement Capsules, 500 mg, 60-Count Bottles (Pack of 2)

Balanceuticals Stomach Fortifier Dietary Supplement Capsules, 500 mg, 60-Count Bottles (Pack of 2)
by Balanceuticals

Dietary supplement. 100% Natural. Made under supervision by China Academy of Traditional Chinese Medicine. This well-known formula is made of ginseng root, poria (Indian bread), attractylodes, common yam, hyacinth bean, coix, ammonium seed, platcodon and licorice. Chinese medicine uses it to strengthen the spleen and stomach, normalize peristalsis of the stomach and intestines, promote absorption of water and chlorine ion, improve metabolism, nurture the lung, balance bowel movements and increase energy. (This statement has not been evaluated by the FDA. This produc is not intended to diagnose, treat, cure of prevent any disease.)

  Surrogate Markers to Assess Efficacy of Treatment in Chronic Liver Diseases (Falk Symposium)
by J. Reichen (Editor), Raoul E. Poupon (Editor)

Recent years have seen an increasing number of supposedly active drugs for the treatment of chronic liver diseases, e.g. ursodeoxycholate for treatment of cholestatic conditions and alpha-interferon for the treatment of chronic viral hepatitis. However, in all controlled studies, hard end-points such as survival or need for transplantation often cannot be obtained, owing to the prolonged course of chronic liver diseases up to the time of hepatic decompensation and death. Therefore, surrogate markers for the different conditions are sorely needed in order to assess the value of these novel treatment modalities. This book, the proceedings of an International Falk Workshop held in Basel, Switzerland, October 23--24, 1995, aims to define surrogate markers and to evaluate...

Metabolic Aspects of Chronic Liver Disease

Metabolic Aspects of Chronic Liver Disease
by Ami Schattner (Editor)

This book discusses in detail new aspects of the metabolic basis of important chronic liver diseases. Entities such as non-alcoholic fatty liver disease (fatty liver and Non-Alcoholic SteatoHepatitis - NASH), diabetes in chronic hepatitis C, hemochromatosis, Wilson's disease, Gaucher disease, porphyria, as well as liver cirrhosis and its metabolic consequences will be discussed in detail. These clinical conditions are highly prevalent and affect millions of patients in the USA and world-wide. For example, non-alcoholic fatty liver disease is the most common cause of elevated liver enzymes in the general population. This field has been practically transformed over the last few years, with many new insights gained, regarding both pathogenesis and effective novel treatments.

  Silence Is Deadly
Directed By: Kindra Ruocco



  Chronic disease reports: deaths from chronic liver disease - United States, 1986.: An article from: Morbidity and Mortality Weekly Report
by U.S. Government Printing Office (Publisher)

This digital document is an article from Morbidity and Mortality Weekly Report, published by U.S. Government Printing Office on November 24, 1989. The length of the article is 803 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Chronic disease reports: deaths from chronic liver disease - United States, 1986.
Publication: Morbidity and Mortality Weekly Report (Newsletter)
Date: November 24, 1989
Publisher: U.S. Government Printing Office
Volume: v38 Issue: n46 Page: p792(4)

Distributed by Thomson...

  Chronic Liver Disease (Frontiers of Gastrointestinal Research)
by M. U. Dianzani (Author), P. Gentilini (Editor)



Balanceuticals Blood Circulator Dietary Supplement Capsules, 500 mg, 60-Count Bottle

Balanceuticals Blood Circulator Dietary Supplement Capsules, 500 mg, 60-Count Bottle
by Balanceuticals

Dietary Supplement. 100% Natural. Made under Supervision by China Academy of Traditional Chinese Medicine. Made of medicinal rhubarb, prepared rehmannia root, common peony root, peach seed, bitter apricot seed, licorice root, scute, dun fly, gadfly, leech, June beetle, this time-honored formula is used in Chinese medicine to promote micro-circulation, increase blood flow to heart muscles, open and clear arteries, inhibit intestinal adhesion, soothe the liver, remove stasis and maintain healthy blood circulation and regular menses. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

© 2009 BrightSurf.com